Álvaro Pinto, Medical Oncologist at University Hospital La Paz, shared a post on X:
“Looks like ESMO25 will be amazing for Urologic Oncology, 4 presentations in Presidential Symposium!! Can’t wait to see the data!”
Proffered Paper sessions:
LBA2 – Perioperative (periop) enfortumab vedotin (EV) plus pembrolizumab (pembro) in participants (pts) with muscle-invasive bladder cancer (MIBC) who are cisplatin – ineligible: The phase 3 KEYNOTE-905 study
Speakers: Christof Vulsteke (Gent, Belgium)
Lecture Time: 16:52 – 17:04
LBA6 – Phase 3 trial of [177Lu]Lu – PSMA – 617 combined with ADT plus ARPI in patients with PSMA-positive metastatic hormone – sensitive prostate cancer (PSMAddition)
Speakers: Scott T. Tagawa (New York, United States of America, US)
Lecture Time: 17:14 – 17:24
LBA7 – Disitamab vedotin (DV) plus toripalimab (T) versus chemotherapy (C) in first – line (1L) locally advanced or metastatic urothelial carcinoma (la/mUC) with HER2 – expression
Speakers: Xinan Sheng (Beijing, China)
Lecture Time: 17:34 – 17:46
LBA8 – IMvigor011: a Phase 3 trial of circulating tumour (ct)DNA-guided adjuvant atezolizumab vs placebo in muscle-invasive bladder cancer
Speakers: Thomas B. Powles (London, United Kingdom)
Lecture Time: 16:30 – 16:42
More posts from Álvaro Pinto on OncoDaily.